Yupelri is a U.S. FDA-approved liquid formulation of the long-acting muscarinic antagonist (LAMA) revefenacin, used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is administered via a standard jet nebulizer [1].
When does Yupelri's exclusivity expire?
The U.S. patent for Yupelri is set to expire in 2032 [2]. Exclusivity periods can vary, and this expiration date indicates when the patent protection is expected to end, potentially allowing for generic competition.
What is the active ingredient in Yupelri?
The active ingredient in Yupelri is revefenacin [1]. Revefenacin is a LAMA that works by relaxing the muscles in the airways, which helps to improve airflow and reduce symptoms of COPD [3].
How is Yupelri administered and what is its dosage?
Yupelri is administered as a solution for nebulization. The recommended dose is 175 mcg of revefenacin, delivered via a standard jet nebulizer, once daily [1].
What are the key benefits of Yupelri for COPD patients?
Yupelri provides 24-hour bronchodilation, helping to improve lung function and reduce symptoms of COPD with once-daily dosing [1]. Its liquid formulation allows for administration with a standard jet nebulizer, a common device for respiratory treatments [1].
Are there any known side effects of Yupelri?
Common side effects reported in clinical trials include nasopharyngitis, headache, and upper respiratory tract infection [1].
How does Yupelri compare to other COPD maintenance treatments?
As a LAMA, Yupelri functions similarly to other LAMAs in relaxing airway muscles. Its efficacy and safety profile are established through clinical trials [1]. Comparisons with other COPD medications, such as other LAMAs, LABAs, or combination therapies, would typically involve assessing differences in efficacy, side effect profiles, dosing frequency, and administration methods.
Can Mylan face patent challenges for Yupelri?
Yes, pharmaceutical patents can be challenged by generic manufacturers. Such challenges, often through the Hatch-Waxman Act in the U.S., aim to bring generic versions of a drug to market sooner than the patent expiration date [4]. Information on specific patent challenges or litigation concerning Yupelri would be available through specialized patent tracking services.
What is the regulatory status of Yupelri?
Yupelri received U.S. Food and Drug Administration (FDA) approval in October 2018 [1].
What is the role of revefenacin in COPD treatment?
Revefenacin is a long-acting muscarinic antagonist (LAMA). LAMAs are a cornerstone of COPD management, working by blocking the action of acetylcholine on smooth muscle cells in the airways, leading to bronchodilation. This effect helps to ease breathing and reduce exacerbations [3].
What are the most common respiratory conditions treated with LAMAs like revefenacin?
LAMAs, including revefenacin, are primarily used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1][3].
How does Yupelri fit into Mylan's portfolio?
Mylan, now part of Viatris, has a portfolio that includes various respiratory medications. Yupelri represents a branded specialty product within their offerings for COPD management [1].
---
Sources:
[1] https://www.yupelri.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530541/
[4] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/andreas-f-hecht-patent-and-exclusivity-information